Protagonist Therapeutics

About:

Protagonist Therapeutics develops orally-stable peptides to treat diseases that are currently addressed by injectable antibodies.

Website: http://www.protagonist-inc.com

Twitter/X: ProtagonistTx

Top Investors: RA Capital Management, MidCap Financial, National Institutes of Health, Foresite Capital, Silicon Valley Bank

Description:

Protagonist Therapeutics is a biotechnology company dedicated to the discovery of novel peptide and small molecule compounds that mimic or inhibit therapeutically-relevant protein-protein interactions.

Total Funding Amount:

$389M

Estimated Revenue Range:

$50M to $100M

Headquarters Location:

Brisbane, Queensland, Australia

Founded Date:

2001-01-01

Contact Email:

info(AT)protagonist-inc.com

Founders:

Mark Smythe

Number of Employees:

51-100

Last Funding Date:

2021-06-14

IPO Status:

Public

© 2025 bioDAO.ai